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Abstract
The laboratory mouse is an ideal model organism for studying disease because it is
physiologically similar to human and also because its genome is readily manipulated. Genetic
engineering allows researchers to introduce specific loss-of-function or gain-of-function mutations
into genes and then to study the resulting phenotypes in an in vivo context. One drawback of using
traditional transgenic and knockout mice to study human diseases is that many mutations passed
through the germline can profoundly affect development, thus impeding the study of disease
phenotypes in adults. New technology has made it possible to generate conditional mutations that
can be introduced in a spatially and/or temporally restricted manner. Mouse strains carrying
conditional mutations represent valuable experimental models for the study of human diseases and
they can be used to develop strategies for prevention and treatment of these diseases. In this
article, we will describe the most widely used DNA recombinase systems used to achieve
conditional gene mutation in mouse models and discuss how these systems can be employed in
vivo.
INTRODUCTION
In the last two decades, gene targeting in embryonic stem (ES) cells has been used
extensively as a tool to generate predesigned mouse mutants for studying gene function in
vivo. In its original form, gene targeting allowed for the disruption of a specific gene in the
mouse germline via insertion of a selectable marker (Capecchi 1989). The vast majority of
the >3000 currently available knockout mouse strains have been created following this
design strategy and many of these mouse models have provided valuable insights into the
biological function of the genes studied. Nevertheless, because these “conventional”
knockout mutations typically result in complete loss of function and are transmitted through
the germline, they frequently result in embryonic or early postnatal lethality.
In 1994, site-specific recombinase systems (e.g., Cre, FLP, Dre) emerged as a technology
that would allow for the design of more refined mouse models of human disease. These
methodologies, along with gene targeting techniques, now make it possible for researchers
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to modify the mouse genome in almost any desired manner, for example by making loss-of-
function or gain-of-function mutations (Lakso et al. 1992) that are spatially and temporally
restricted (Lobe and Nagy 1998; Nagy and Rossant 2001). Consequently, gene function in
adult mice can be precisely studied at a specific developmental stage or in a specific cell/
tissue type of choice. Human diseases that arise late in life or in specific tissues (e.g.,
neurodegeneration or cancer) can now be studied effectively in an experimental organism.
SITE-SPECIFIC RECOMBINASES
Cre (cyclization recombination) is a 38 kDa, site-specific DNA tyrosine recombinase
derived from P1 bacteriophage. It catalyzes DNA recombination between two 34-bp
recognition sequences referred to as loxP sites (locus of crossing over {X} of P1). Since Cre
does not require high-energy cofactors or accessory proteins and exhibits optimal
recombinase activity at 37°C (Buchholz et al. 1996), the system is optimal for genetic
engineering in cultured mammalian cells and in mice. Each loxP site is composed of two 13-
bp palindromic sequences that are separated by an 8-bp asymmetric core region that
determines the orientation (Fig. 1A, Table 1). Owing to its size, the loxP site is unlikely to
be F1 T1 found at random in the mouse genome (Nagy 2000). Upon binding to the loxP
sites, Cre-mediated recombination results in cleavage of the DNA and reciprocal strand
exchange between the two loxP sites (Grindley et al. 2006). The orientation of the two-loxP
sites determines the different DNA products that are produced (Fig. 1B–D). When two loxP
sites are arranged in the same orientation on a linear DNA fragment, Cre-mediated
recombination results in excision of the loxP-flanked DNA fragment in a circular form,
leaving behind a single loxP site on the linear DNA. When two loxP sites are arranged in
opposite orientation to each other on a linear DNA fragment, Cre-mediates the inversion of
the loxP-flanked DNA fragment. Cre can also exchange DNA sequences that are distal to
the loxP sites on two different linear DNA fragments, such as a pair of nonhomologous
chromosomes (Branda and Dymecki 2004).
A drawback of the Cre/lox system is that DNA methylation, transcriptional activity, and
chromatin structure at the locus of interest, and the distance between the loxP sites, can
influence the efficiency of recombination (Vooijs et al. 2001). To increase expression and
enhance the enzymatic activity of Cre protein, the cre gene has been modified to create a
new recombinase variant. These changes include a reduced CpG content, several silent
mutations, and an improved Kozak translation initiation consensus sequence. The encoded
iCre (improved Cre) demonstrated a 1.6-fold increase in expression over the conventional
Cre when expressed from the same vector in mammalian cells. iCre was also found to be
1.8-fold more efficient at DNA recombination than conventional Cre (Shimshek et al. 2002).
FLP (Flippase) is a tyrosine recombinase that was originally isolated from Saccharomyces
cerevisiae (Sadowski 1995). Similar to Cre, FLP alters the arrangement of DNA by strand
cleavage, exchange, and ligation. The FLP recombinase mediates DNA recombination
between two 34-bp recognition sites referred to as FRT (Flippase Recognition Target),
which have a similar structure to loxP sites (Fig. 1A, Table 1). Like Cre, FLP does not
require high-energy cofactors or accessory proteins to catalyze recombination, but unlike
Cre, it exhibits optimal activity at 30°C and is unstable at 37°C (Buchholz et al. 1998).
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Mutational analysis of FLP resulted in the identification of FLPe, which exhibits improved
thermostability at 37°C, but this mutant is still less stable compared to Cre (Buchholz et al.
1998). FLPe exhibits a 4-fold increase in recombinase activity over wild-type FLP when
analyzed in culture. In mice, FLPe can readily mediate recombination between FRTs
separated by as little as a few kilobases or as much as 150 kb (Farley et al. 2000;
Awatramani et al. 2003). Despite this improvement, the recombination efficiency of FLPe
still remains low in cells (Farley et al. 2000). To improve the translational efficiency in
mammalian cells, FLPe was re-engineered de novo according to the native amino acid
sequence, but with mouse codon usage. The base composition of the codon-optimized FLPe
gene (FLP optimized or FLPo) was modified to prolong mRNA half-life, and two stop
codons were also included to ensure efficient translational termination. FLPo was shown to
exhibit enhanced recombinase activity comparable to Cre (Raymond and Soriano 2007).
Other recombinases have also been identified for genome engineering in mice. For example,
comparative analysis of P1-like phages identified Dre recombinase from the bacteriophage
D6. Dre is also a tyrosine recombinase that is able to catalyze site-specific recombination in
a similar manner to Cre, but it recognizes a recombination target site that is distinct from
loxP. The rox site is a 32-bp DNA sequence that consists of two 14-bp inverted repeats that
are separated by a 4-bp asymmetric core region (Table 1). Owing to a difference in amino
acid sequence between Cre and Dre at the DNA recognition site, Dre is not able to catalyze
recombination at loxP and Cre cannot catalyze recombination at rox (Sauer and McDermott
2004). The Dre-rox system has been shown to function both in mammalian cells and in
mice, and therefore may be used in conjunction with the Cre-lox system for genome
engineering. The Dre-rox system is relatively new with only three ubiquitous mouse lines
developed based on the CAGGs promoter and the Rosa26 locus (Anastassiadis et al. 2009).
TRANSGENIC EXPRESSION OF CRE
The high efficiency of the Cre-loxP system in mammalian cells (Gu et al. 1994; Sauer 1994)
has led to its common use for genetic engineering in vivo. The in vivo delivery of Cre to
cells in a mouse can be achieved in several ways. For example, animals carrying a
conditional allele of a gene, typically flanked by two loxP sites (“floxed” allele) in the
desired orientation, can be crossed with animals carrying a transgene or knock-in that
expresses Cre under the control of a promoter that restricts its expression to a particular
developmental stage, a particular tissue, or a particular cell type (Fig. 2A, Table 2). In the
absence of Cre recombinase, mice carrying two floxed alleles will express wild-type protein
at endogenous levels. Cross-breeding with a Cre strain will lead to inactivation of the
targeted gene within the expression domain of the recombinase, while the target gene
remains intact in other cells where the recombinase is not expressed.
The Cre-lox system can also be used to obtain gain-of-function mutations to generate new
models of human cancer. Mice harboring a conditionally activatable allele of oncogenic K-
ras have been used to generate various mouse models of human cancer, including lung
adenocarcinoma (Jackson et al. 2001). Expression of oncogenic K-ras is controlled by a
removable transcriptional stop element (Lox-STOP-LOX). In the presence of Cre, the STOP
element is removed and oncogenic K-ras is expressed only in cells where the recombinase is
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expressed (Tuveson et al. 2004). Combining gain-of-function and loss-of-function mutations
has led to the development of more advanced cancer models (Babaei-Jadidi et al. 2011;
Young et al. 2011).
Using this standard approach, recombinase expression, and theoretically, the timing and
pattern of gene mutation are entirely dependent on the endogenous activity of the chosen
promoter. Practically, however, the desired tissue specificity and the level of induction are
difficult to control in a transgenic line, often resulting in mosaic expression of the
recombinase or expression in unwanted tissues (Schwenk et al. 1998; Rossant and
McMahon 1999) (Fig. 3). Despite this limitation, this approach has been utilized effectively
for modeling human diseases such as cancer. For example, specific mutation of Apc and
Rb1 in the intestinal epithelium effectively induces adenocarcinoma (Kucherlapati et al.
2008).
While many successful Cre transgenic mice have been generated and used in laboratories,
several caveats have been reported. For example, because the mammalian genome does not
contain endogenous loxP sites, expression of Cre in mice was expected to be harmless.
Nevertheless, several incidences of Cre toxicity both in vitro and in vivo have been reported
(Loonstra et al. 2001; Forni et al. 2006). To minimize the toxic effect of Cre, a self-deleting
retroviral vector that incorporates a negative feedback loop limiting the duration and
intensity of Cre expression has been engineered. The vector carries the Cre cDNA and a
single loxP site in its U3 region of the 3’LTR, which allows for transient expression of Cre
in the target cell and subsequent deletion from the genome in a Cre-dependent manner
(Pfeifer et al. 2001; Silver and Livingston 2001). Additionally, even tissue-restricted
mutation of a gene can be lethal when it occurs early during development (Braun et al.
2004). There are two ways to overcome these limitations: (1) by using transgenic mouse
strains in which the expression or activity of Cre can be regulated acutely and (2) through
exogenous delivery of Cre, for example, by using viruses.
ACUTE REGULATION OF CRE ACTIVITY
There are several ways to regulate recombinase activity acutely, for example, by driving Cre
expression from a promoter that is induced by treatment of mice with a particular chemical.
In the AhCre strain, Cre expression is under the control of the rat cytochrome P450 1A1
(CYP1A1) promoter element that is transcriptionally up-regulated in response to β-
napthanoflavone. As such, Cre-mediated recombination is only induced following injection
with β-napthanoflavone (Ireland et al. 2004). This approach has been used to study the
effects of deleting Apc and c-Myc in the intestinal epithelium, where the CYP1A1 promoter
is strongly induced (Sansom et al. 2007). In Mx1-Cre mice, Cre is under the control of the
Mx1 promoter, which is strongly induced in hematopoietic cells and in the liver by
administration of interferon α and β, or polyriboinosinic acid/polyribocytidylic acid (poly
I:C) (Kuhn et al. 1995). Mx1-Cre mice were crossed with animals carrying conditional
mutations in Kras (Braun et al. 2004) and Nras (Li et al. 2011) to model myeloproliferative
disease and myeloid leukemia.
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One particularly successful strategy has involved fusing a mutant estrogen receptor (ER)
ligand binding domain (LBD) to the C terminus of Cre (Metzger et al. 1995; Schwenk et al.
1998). Addition of the ligand (4-OH tamoxifen {4-OH}) allows CreER to access the nucleus
in an active conformation leading to Cre-mediated recombination (Indra et al. 1999). A more
powerful approach to study human disease is the development of inducible gene expression
systems with tissue-restricted expression of these fusions using specific enhancer elements
to gain both temporal and spatial control over recombinase and gene activity (Logie and
Stewart 1995; Danielian et al. 1998).
Another approach used for temporal regulation in transgenic mouse models is the reverse
tetracycline-regulated gene expression system (Gossen and Bujard 1992). In this system a
transgenic mouse line is produced in which the promoter driving Cre expression contains a
tetracycline-responsive promoter element (tetO). In the presence of doxycycline, the
inducer, Cre is rapidly expressed, thus allowing gene deletion (Lewandoski 2001). While
this system has been successfully used, the main disadvantage of this approach is the
complexity of the tripartite system, which complicates mouse husbandry due to the mating
of the three different transgenic lines.
Although ligand-inducible recombinase systems have opened new avenues in experimental
biology, temporal control of recombinase activity is limited by the time required for cell/
tissue permeation. They also require systemic administration of the inducer, making it
difficult to restrict Cre induction to a small area. Recently developed light-switchable
transgene systems could provide precise and robust spatiotemporal control over gene
expression in both cultured cells and mice (Kennedy et al. 2010; Wang et al. 2012). This
system takes advantage of genetically encoded dimerization modules based on plant
photoreceptors that control protein–protein interactions by light (Shimizu-Sato et al. 2002;
Levskaya et al. 2009). Arabidopsis light oxygen voltage (LOV) domain-containing proteins
(e.g., CIB1 and CRY2) form dimers upon exposure to blue-light (Zoltowski and Crane
2008). Artificial dimerizers can be engineered to allow inducible control of a “split” protein,
in which two inactive fragments are brought together to reconstitute functional protein
activity. Using this system a split Cre recombinase can be fused to CIB-CRY modules,
allowing light-dependent control of DNA recombination (Jullien et al. 2003; Kennedy et al.
2010). These modules are transferred into mice using a hydrodynamic procedure and can be
activated by two-photon stimulation, which is ideal when using mice, illustrating high
induction with fast kinetics (Wang et al. 2012).
VIRAL DELIVERY OF CRE
A major limitation of transgenic approaches to providing Cre to cells is that it is extremely
difficult to limit expression to a small population of cells. In many cases (e.g., investigations
of immune responses), it is desirable to mutate a gene broadly within a specific tissue or cell
type. For modeling certain disease states (e.g., cancer), however, it is actually preferable to
target only a small population of cells. Adenoviruses and lentiviruses can be used to
effectively deliver genes to both dividing and nondividing cells in vivo (Wang et al. 1996)
and, because the viruses can be delivered directly (e.g., by injection) into specific anatomic
locations in animals carrying conditional alleles, the extent of the conditional genetic
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modification can be restricted to a small area of viral spread. Adenoviral delivery is
advantageous because the viral DNA does not integrate into the host genome. As such,
expression of genes carried by the recombinant virus is transient. Adenovirus is
disadvantageous, however, because it elicits a host immune response. Lentiviruses, by
contrast, stably integrate into the genome, providing sustained transgene expression and they
generate little or no immune response (Naldini et al. 1996; Lai et al. 2002). Since these
viruses integrate into the host genome, however, they can induce mutation of host genes,
which is a concern for experimental studies. In comparison to other viral systems, lentiviral
vectors have a larger insert capacity, thus large gene inserts, longer (e.g., tissue-specific)
promoters, and more than one gene (poly-cistronic cassettes) can be subcloned into the
vectors (Heldt and Ressler 2009). The production of Cre-containing lentiviruses in tissue
culture cells and subsequent purification are detailed in Producing and Concentrating Lenti-
Cre for Mouse Infections (Gierut et al. 2014a).
Viral delivery approaches have been used extensively to model cancer in mouse models. For
example, acute infection of the respiratory epithelium via intranasal instillation (see In vivo
Delivery of Lenti-Cre or Adeno-Cre using Intranasal Instillation [Gierut et al. 2014b]) or
intratracheal injection of Adeno-Cre induces non-small-cell lung cancer in animals carrying
conditional alleles Kras and Trp53 (Jackson et al. 2005) and small-cell lung cancer in
animals carrying conditional alleles Rb1 and Trp53 (Vooijs et al. 1998; Jonkers et al. 2001;
Meuwissen et al. 2003). Similarly lentiviral vectors have been engineered to introduce both
Cre recombinase and exogenous antigens in order to mimic tumor neoantigens. For
example, intranasal instillation of Lenti-Cre vectors that also express T-cell antigens into
animals carrying a conditional allele of Kras led to tumors that had large numbers of
infiltrating lymphocytes, including both T and B cells, several weeks after tumor initiation
(DuPage et al. 2011). Intracranial injection of Adeno-Cre into mice carrying conditional
alleles of Egfr and Arf or Pten generates a rapid-onset high-grade malignant glioma
phenotype that is molecular and pathologically similar to glioblastoma multiforme (GBM) in
humans.
VALIDATION OF CRE ACTIVITY
A useful exercise when generating new transgenic Cre strains, or when analyzing
phenotypes associated with conditional mutation of a specific gene, is to characterize the
pattern of expression of the recombinase using Cre reporter strains. The reporter strain
contains a floxed transcriptional stop sequence that prevents the expression of the
downstream reporter gene (usually β-galactosidase or GFP) in the absence of Cre (Soriano
1999). When crossed with a Cre transgenic mouse strain or after infection with the virus, the
stop element is removed and the reporter gene is expressed in tissues where Cre is expressed
(Fig. 3). This procedure is detailed in Whole Mount X-Gal Staining of Mouse Tissues
(Gierut et al. 2014c). If the expression pattern of the Cre strain is unknown, one should first
perform whole mount staining of all the major mouse tissues in order to assess the Cre
activity throughout the entire body of the mouse. When using an established Cre strain or
viral infection, histological sections of the specific tissue(s) should be analyzed in order to
obtain detailed information about the regional and cell type-specific expression of the
recombinase.
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DUAL RECOMBINASE TECHNOLOGY
Because many diseases result from the combined effects of multiple mutations, it is often
desirable to combine conditional alleles together. This creates a potential problem because
Cre can promote both intragenic and intergenic recombination (Fig. 1A). As a result, the
combination of multiple conditional alleles can lead to undesired genomic arrangements. To
overcome this limitation, variant Cre and Flp target sites can be used in different conditional
alleles (Table 1) (Hoess et al. 1986; Senecoff et al. 1988). In this situation, recombination is
proficiently mediated between pairs of homotypic (loxP/loxP or lox2272/lox2272) but not
heterotypic (loxP/lox2272) sites (Senecoff and Cox 1986). Likewise, for Flp-mediated
recombination, the spacer variants F3 and F5 have been shown to be insensitive to
recombination with wild-type FRT sites (Schlake and Bode 1994). In contrast, the Cre target
site lox511 (Bethke and Sauer 1997) has been found to recombine (1%–5%) with a wild-
type loxP site (Kolb 2001) and therefore it is less effective for this type of gene inactivation
strategy (Table 1).
While Cre-mediated deletion is essentially unidirectional, inversion is reversible and
therefore not used for stable gene alternations in cells that express Cre. Site-directed
mutagenesis of wild-type loxP sites has led to the identification of variant loxP pairs that
display a favorable forward reaction and for unidirectional Cre-mediated inversion (Albert et
al. 1995). Cre-mediated recombination of the two asymmetric, mutant loxP sites, lox66
(right) and lox71 (left), yields one loxP site with two mutated inverted repeats (lox72) and
one wild-type loxP site. Although successful application of lox66/71 mediated
recombination has been observed in mouse ES cells (Araki et al. 1997; Zhang and Lutz
2002), an in-depth characterization of lox66/lox71 recombination in Cre-transgenic mouse
strains has yet to be determined.
As an alternative to using distinct recognition sites for the same recombinase, conditional
alleles for different recombinases can be combined. Dual recombinase technology has
become a major area of study and interest because (1) it enables distinct gene mutations to
be directed to different cell types and (2) it allows for sequential mutation of genes. For
example, a Cre-dependent allele of Trp53 and a FRT-dependent allele of Kras were
combined to examine the effects of sequential mutations on the development of soft tissue
sarcoma (Young et al. 2011).
FUTURE DIRECTIONS
The completion of the human and mouse genome sequencing projects, together with
advances in site-specific recombinase technology, herald a new era of genetic analysis in the
mouse. The original Cre and FLP recombinases demonstrated their utility in developing
conditional gene targeting. Now, other analogous recombinases are ready to be used, in the
same way or in combined strategies, to achieve more sophisticated experimental schemes for
addressing complex biological questions. The properties of site-specific recombinases, in
combination with other tools (tet on/off system, siRNA mediating gene silencing,
fluorescent proteins, viral vectors, etc.), make them useful instruments to induce precise
mutations in specific cells/tissues and in a temporally controlled manner. This spatially and
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temporally controlled activity can be applied to functional genomics in many ways: from
conditional and inducible gene targeting to controlled expression of transgenes and
recombination-mediated cassette exchange in mouse models. Indeed, with the tools of site-
specific recombinase technology in hand, the field of mouse genetics is primed to determine
the contribution of the vast majority of genes to development and disease.
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FIGURE 1.
Cre and FLP recognition sequences and mechanism of recombination. (A) The Cre
recombinase recognition sequence is termed loxP (black arrow), while the Flp recombinase
recognition sequence is termed FRT (gray arrow). Both loxP and FRT contain two 13-bp
inverted repeats that are separated by an 8-bp spacer region. (B) Cre mediates excision or
circularization of a DNA segment (white rectangle) when flanked by two loxP sites (black
triangles) in a cis (same DNA strand) arrangement and oriented in the same direction. (C)
Cre mediates inversion of a DNA segment (black arrow) when flanked by two loxP sites
(black triangles) in a cis arrangement and oriented in the opposite direction. (D) Cre
mediates translocation of a DNA segment (rectangles) when the loxP sites (black triangles)
are located on different strands of DNA (trans arrangement) and are oriented in the same
direction.
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FIGURE 2.
Breeding schemes for generating Cre-lox conditional, tissue-specific mutant mice. (A)
Classical Cre-lox strategy to obtain conditional gene knockout in a tissue-specific manner.
Mice harboring the conditional allele are crossed with Cre transgenic mice, in which Cre
recombinase is under the control of a tissue-specific promoter (TSP). Breeding of these two
mice will produce heterozygous offspring with excision of the floxed gene of interest only in
the Cre-expressing cells/tissue (gray), while the gene of interest remains functional in other
cell/tissue types (white). Offspring that are heterozygous for the conditional allele and also
contain the Cre transgene (G1) are crossed to homozygous conditional mutant mice.
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Offspring that are homozygous for the conditional allele and heterozygous for the Cre
transgene (G2) represent the conditional deletion mice, which can be generated at a
frequency of 25%. Littermates that are homozygous for the conditional allele but do not
carry the Cre transgene can be used as experimental controls. (B) Ligand-inducible strategy
to obtain conditional gene knockout. Mice harboring the conditional allele are crossed with
mice carrying a CreER fusion protein that is under the control of a tissue specific promoter
(TSP). Breeding of these two mice will produce heterozygous offspring that contain the
floxed gene of interest and the CreER fusion transgene. These animals are crossed to
homozygous conditional mutant mice (G1). Offspring that are homozygous for the
conditional allele and heterozygous for the CreER transgene (G2) can be generated at a
frequency of 25% and represent the experimental animals. In the presence of ligand
(tamaxofin [4-OH]) the floxed gene of interest will be excised only in the CreER-expressing
cells/tissue (gray), while the gene of interest remains functional in other cell/tissue types
(white). Control animals are treated with vehicle and the floxed gene of interest remains
functional in all cell/tissue types since the CreER transgene is not activated by the ligand.
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FIGURE 3.
Cre expression mediated by the “tissue-specific” liver fatty acid binding protein (Fabpl)
promoter. (A) High magnification of β-galactosidase staining in whole mount of the distal
small intestine from Fabpl-Cre/+; R26R/+ mice. Cre-positive portions of the tissue stain
blue when exposed to X-Gal. The Fabpl-Cre transgene directs expression of Cre
recombinase to the distal small intestine and colon. (B) β-galactosidase expression in a
paraffin section of the distal colon from Fabpl-Cre/+; R26R/+ mice. The expression of the
Cre transgene is mosaic and therefore normal (white) and mutant (blue) crypts can be
analyzed in the same mouse. (C) High magnification of β-galactosidase staining in whole
mount of the urinary tract from Fabpl-Cre/+; R26R/+ mice. The positive staining (blue)
illustrates the off-target effects that can be attained using this system.
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TABLE 1
Cre, FLP, and Dre recognition sites: classical and variant sites
Recombinase Recognition Site Inverted Repeat 1 Spacer Inverted Repeat 2
Cre loxP ATAACTTCGTATA ATGTATGC TATACGAAGTTAT
Cre lox2272 ATAACTTCGTATA ATGTGTAC TATACGAAGTTAT
Cre lox511 ATAACTTCGTATA ATGTATAC TATACGAAGTTAT
Cre lox m2 ATAACTTCGTATA AGAAACCA TATACGAAGTTAT
Cre lox66 ATAACTTCGTATA ATGTATGC TATACGAACGGTA
Cre lox71 TACCGTTCGTATA ATGTATGC TATACGAAGTTAT
Cre lox72 TACCGTTCGTATA ATGTATGC TATACGAACGGTA
FLP FRT GAAGTTCCTATTC TCTAGAAA GTATAGGAACTTC
FLP F3 GAAGTTCCTATTC TTCAAATA GTATAGGAACTTC
FLP F5 GAAGTTCCTATTC TTCAAAAG GTATAGGAACTTC
Dre rox TAACTTTAAATAAT GCCA ATTATTAAAGTTA
Nucleotides, in the variant sites, that have been altered from the classical sites are underlined.
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TABLE 2
Tissue-Specific Cre-Expressing Mouse Lines
Specificity Promoter Transgene Reference
Ubiquitous Human cytomegalovirus (CMV) CMV-Cre
CreERT2 CMV
Schwenk et al. (1995), Feil et al. (1996)
Ubiquitous Rosa26 Rosa26-Cre Soriano (1999)
Adipocytes aP2 aP2-Cre Barlow et al. (1997)
B-lymphocytes CD-19 gene albumin Cd19-Cre
Cd-19-CreERT2
Rickert et al. (1997), Boross et al. (2009)
Brain (neurons) Calbindin 2 Calb2-CreERT2 Taniguchi et al. (2011)
Cardiac muscle α-Myosin heavy chain (α-MHC) α-MHC-Cre Gupta et al. (1998)
Central nervous system
 (hippocampus)
Mouse pro-opiomelanocortin-alpha (POMC) POMC-Cre McHugh et al. (2007)
Colonic epithelium Human caudal type homeo-box 2 (CDX2) CDX2-Cre Hinoi et al. (2007)
Epiblast cells Mouse SRY-box containing gene 2 (Sox2) Sox2-Cre Hayashi and McMahon (2002)
Kidney epithelium Gamma-glutamyltransferase 1(Ggt1) Ggt1-Cre Iwano et al. (2002)
Liver (hepatocytes) Albumin promoter/enhancer (Alb) Alb-Cre
Alb-CreERT2
Postic and Magnuson (1999), Schuler et al.
(2004)
Lung (endoderm) Human surfactant pulmonary-associated
 protein C (SFTPC)
SFTPC-Cre Okubo and Hogan (2004)
Mammary gland Whey acidic protein (Wap) Wap-Cre Wagner et al. (1997)
Midbrain/hindbrain Mouse engrailed 2 promoter/enhancer (En2) En2-Cre Sgaier et al. (2005)
Pancreatic epithelium Pancreatic and duodenal homeobox1 (pdx1) Pdx1-Cre Gannon et al. (2000a)
Pancreatic β-cells Rat insulin II Ins2-Cre Gannon et al. (2000b)
Skeletal muscle Mouse muscle creatine kinase (MCK) MCK-Cre Levin et al. (2007)
Skin (keratinocytes) Human keratin 14 K14-Cre
K14-CreERT2
Dassule et al. (2000), Vasioukhin et al.
(1999)
Small and large intestine
 (crypts)
Mouse villin 1 Vil-Cre
Vil-CreERT2
Madison et al. (2002), Vasioukhin et al.
(1999)
Small and large intestine
 (epithelium)
Fatty acid binding protein (Fabp) Fabpl-Cre Saam and Gordon (1999)
Small and large intestine
 (epithelium)
Leucine-rich repeat-containing G-protein
 coupled receptor 5 (Lgr5)
Lgr5-EGFP-IRES-
CreERT2
Barker et al. (2007)
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